Novel Agent Reduces Monthly Migraine Days
MedPage Today) -- A monoclonal antibody targeting a novel migraine prevention pathway showed success in the phase II HOPE trial.
Menu
Menu
- 22/06/2025 09:19 Una nueva ley de Texas exigirá exhibir los 10 Mandamientos en aulas de escuelas públicas
- 22/06/2025 09:19 EEUU ataca tres sitios nucleares iraníes, involucrándose en la guerra de Israel con Irán
- 22/06/2025 09:19 Luis Ortiz conduce a Guardianes a una victoria 4-2 sobre Atléticos
- 22/06/2025 07:20 Bulawayo Father Runs Over, Kills Own Daughter, 2, While Reversing
- 22/06/2025 07:20 Widow Arrested In Dramatic Fight Over Late ZANU PF MP Farai Taruvinga’s Multi-Million Dollar Estate
- 22/06/2025 07:20 Here’s Why Proteas Captain Temba Bavuma Was Ruled Out of Zimbabwe Test Series
- 22/06/2025 05:20 New listings slowdown shows lack of home seller stress in 2025
- 22/06/2025 05:20 Tech Pulse: Longbridge talks AI senior inclusivity, UWM details lending advancements
- 22/06/2025 05:20 Title tech firm Dono appoints revenue head
- 22/06/2025 03:20 U.S. strikes Iran’s nuclear facilities
